Indivior Pharmaceuticals (INDV) Income from Continuing Operations (2024 - 2026)

Indivior Pharmaceuticals' Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 89000000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 85.42% year-over-year to 89000000.0; the TTM figure through Mar 2026 stood at 251000000.0 (up 3685.71% YoY), while the FY2025 annual figure was 210000000.0, up 2900.0% from the prior year.
• Income from Continuing Operations was 89000000.0 for Q1 2026 at Indivior Pharmaceuticals, down from 102000000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 102000000.0 in Q4 2025 to a low of 98000000.0 in Q2 2024.
• Historically, Income from Continuing Operations has averaged 34000000.0 across 3 years, with a median of 42000000.0 in 2025.
• Biggest YoY gain for Income from Continuing Operations was 385.71% in 2025; the steepest drop was 22.58% in 2025.
• A 3-year view of Income from Continuing Operations shows it stood at 21000000.0 in 2024, then soared by 385.71% to 102000000.0 in 2025, then slipped by 12.75% to 89000000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 89000000.0 (Q1 2026), 102000000.0 (Q4 2025), and 42000000.0 (Q3 2025), per Business Quant data.